Regulation and Products


In 2009, we won a hard-fought campaign that led to Congress passing a law granting the U.S. Food and Drug Administration (FDA) the authority to regulate all tobacco products, including cigarettes, e-cigarettes, cigars and hookah. Yet, it took the FDA seven years to begin their oversight of many of these products with much more work left to be done. 

Recent spikes in the use of e-cigarettes makes clear that more must be done to regulate tobacco products and the industry's deceptive marketing practices.  We are working to ensure the government fully leverages the regulatory power it now possesses to protect children and adults. 

Tobacco use costs our nation nearly $300 billion in health care and productivity losses each year.

Latest Updates

December 23, 2021

The Food and Drug Administration (FDA) today authorized the marketing of two low-nicotine cigarettes as “modified risk tobacco products,” including one product that is menthol-flavored.

December 17, 2021
New York

ACS CAN looks forward to working with the new New York City Mayor and City Council Speaker on crucial health issues.

December 14, 2021

The U.S. Food and Drug Administration (FDA) opposed public health groups’ request that the agency provide regular status reports to a U.S. District Judge and estimate the dates it expects to complete its review of applications for products that rank among the top 10 brands in market share.

October 12, 2021

The Food and Drug Administration announced this afternoon it has issued marketing orders for the first e-cigarette products authorized by the agency.

Regulation and Products Resources

In order to effectively reduce tobacco use, it is important to understand the impact of the retail availability of tobacco products. The presence of tobacco retailers can undermine a community’s ability to establish tobacco-free social norms by increasing accessibility to tobacco products including e-cigarettes and increasing exposure to tobacco industry point of sale advertising, marketing and promotions. 

Because JUUL’s products continue to have the largest share of the e-cigarette market, and therefore presumably are undergoing expedited review, we write at this time to express our conclusion that based on all of the publicly available evidence, no JUUL product currently on the market can meet the statutory public health standard. Therefore, they should not receive a marketing order.